Acute Heart Failure: Insights on Risk Stratification, Management and Treatment

A special issue of Medicina (ISSN 1648-9144). This special issue belongs to the section "Cardiology".

Deadline for manuscript submissions: closed (31 August 2021) | Viewed by 2279

Special Issue Editor


E-Mail Website
Guest Editor
Department of Cardiology, University Clinical Hospital, 46010 Valencia, Spain
Interests: heart failure; cardiac Imaging; cardiomyopathies; valvular heart disease
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Heart failure, the focus of this Special Issue, is a major and growing public health problem. About 26 million adults worldwide are living with heart failure. Patients with heart failure are on a downward spiral, with frequent hospitalizations for acute heart failure and high mortality rates posing a significant economic burden on healthcare systems and caregivers, deeply affecting patient´s quality of life. However, research on heart failure is an exciting field, and recent years have been witness to important progress in prevention, risk stratification, diagnosis, management, and treatment of heart failure. However, despite recent advances in chronic heart failure management, evidence on acute heart failure is scarcer. In this Special Issue of the journal, we invite you to consider contributing an original investigation, research paper or review article to any aspect related to acute heart failure management and treatment. This is an opportunity for physicians or researchers involved in heart failure to contribute to this exciting field and to the remarkable journey of advances in its management and therapeutics.

Dr. Enrique Santas
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Heart failure
  • Biomarkers
  • Cardiac imaging
  • Therapeutics
  • Devices
  • Risk stratification
  • Prognosis

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Other

6 pages, 6040 KiB  
Case Report
Acute Heart Failure in a Patient with Occult Barlow’s Disease Receiving Bevacizumab
by Toshihide Izumida, Teruhiko Imamura, Yohei Ueno, Kazuaki Fukahara and Koichiro Kinugawa
Medicina 2021, 57(10), 998; https://0-doi-org.brum.beds.ac.uk/10.3390/medicina57100998 - 22 Sep 2021
Cited by 2 | Viewed by 1835
Abstract
Bevacizumab is a recombinant humanized monoclonal antibody and a key drug for treatment of various types of cancer. Bevacizumab is associated with the occurrence of heart failure, but its risk factors remain unknown. A 55-year-old woman was diagnosed with cervical cancer, which was [...] Read more.
Bevacizumab is a recombinant humanized monoclonal antibody and a key drug for treatment of various types of cancer. Bevacizumab is associated with the occurrence of heart failure, but its risk factors remain unknown. A 55-year-old woman was diagnosed with cervical cancer, which was completely treated by bevacizumab-incorporated chemotherapy. During the 9-month bevacizumab therapy, she suffered from hypertension requiring multiple antihypertensive agents. She was admitted to our hospital due to acute heart failure with afterload mismatch and severe mitral regurgitation. A transesophageal echocardiography showed Barlow’s disease with a degenerated and widely prolapsed mitral valve. She received a scheduled surgical mitral valve repair. Post-operative cause was uneventful, but metastatic dissemination developed later. The existence of mitral valve regurgitation, even when sub-clinical, might be a risk of worsening heart failure during bevacizumab therapy. Careful follow-up at an onco-cardiology clinic is highly encouraged particularly for such a cohort during bevacizumab therapy. Full article
Show Figures

Figure 1

Back to TopTop